David Alan Campbell Sells 8,072 Shares of Janux Therapeutics (NASDAQ:JANX) Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) CEO David Alan Campbell sold 8,072 shares of the firm’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $13.73, for a total transaction of $110,828.56. Following the completion of the transaction, the chief executive officer directly owned 284,982 shares in the company, valued at $3,912,802.86. This trade represents a 2.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Janux Therapeutics Stock Performance

NASDAQ:JANX opened at $13.65 on Friday. Janux Therapeutics, Inc. has a one year low of $13.52 and a one year high of $61.59. The stock has a market cap of $821.05 million, a PE ratio of -8.13 and a beta of 2.88. The stock has a 50 day moving average price of $22.51 and a 200 day moving average price of $23.75.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.21. The company had revenue of $10.00 million for the quarter, compared to analyst estimates of $3.07 million. As a group, analysts predict that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Stifel Nicolaus decreased their target price on shares of Janux Therapeutics from $46.00 to $38.00 and set a “buy” rating on the stock in a report on Tuesday, December 2nd. Wall Street Zen raised shares of Janux Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Cantor Fitzgerald lowered their price objective on Janux Therapeutics from $200.00 to $150.00 and set an “overweight” rating for the company in a research report on Tuesday, December 2nd. Wedbush restated an “outperform” rating and issued a $45.00 target price (down previously from $76.00) on shares of Janux Therapeutics in a research report on Tuesday, December 2nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Janux Therapeutics in a research note on Wednesday, October 8th. Twelve equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Janux Therapeutics has an average rating of “Moderate Buy” and an average price target of $61.08.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in JANX. Osaic Holdings Inc. grew its stake in shares of Janux Therapeutics by 704.6% in the second quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock valued at $80,000 after buying an additional 3,037 shares in the last quarter. Virtus Investment Advisers LLC boosted its holdings in Janux Therapeutics by 37.9% during the 2nd quarter. Virtus Investment Advisers LLC now owns 3,679 shares of the company’s stock valued at $85,000 after acquiring an additional 1,011 shares during the period. Tower Research Capital LLC TRC grew its position in Janux Therapeutics by 175.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock valued at $91,000 after acquiring an additional 2,502 shares in the last quarter. Ameritas Investment Partners Inc. increased its stake in Janux Therapeutics by 25.6% during the second quarter. Ameritas Investment Partners Inc. now owns 4,020 shares of the company’s stock worth $93,000 after purchasing an additional 820 shares during the period. Finally, Winthrop Capital Management LLC acquired a new stake in shares of Janux Therapeutics during the third quarter worth about $106,000. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Key Janux Therapeutics News

Here are the key news stories impacting Janux Therapeutics this week:

• Negative Sentiment: CEO David Alan Campbell sold 8,072 shares (~$110,829); he still holds 284,982 shares. Form 4 – Campbell
• Negative Sentiment: Insider Thomas Diraimondo sold 2,505 shares (~$34,394); remaining position ~124,425 shares. Form 4 – Diraimondo
• Negative Sentiment: Zachariah McIver sold 2,714 shares (~$37,263); post-sale holding ~23,286 shares. Form 4 – McIver
• Negative Sentiment: VP Maria Dobek sold 1,462 shares (~$20,073); holds ~15,373 shares after the sale. Form 4 – Dobek
• Negative Sentiment: Insider Charles M. Winter sold 2,401 shares (~$32,966); remaining holding ~77,721 shares. Form 4 – Winter

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.